Bellafill® Receives FDA Approval For Treatment Of Acne Scars - Bellafill® is the only filler on the market approved in the U.S. for the correction of acne scars - Proven safe and effective in a well-controlled clinical study, Bellafill® addresses an unmet need for millions who suffer from acne scarring - Bellafill® is a simple in-office treatment that offers immediate correction and lasting results

January 7, 2015 8:55 PM

24 0

SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, announced today that the U.S. Food and Drug Administration (FDA) has approved the dermal filler, Bellafill®, for the treatment of acne scars. Bellafill® represents a significant clinical advancement as the only filler on the market approved for this disfiguring skin condition. Acne is the most common skin disorder in the U.S., affecting 40-50 million people1 and up to 95% of people with acne may go on to suffer from scarring.2 Bellafill® was studied extensively prior to its FDA approval and proven to be safe and effective for the correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years.

"These types of acne scars affect millions of people and can have a profoundly negative impact on their self-esteem and self-confidence," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. "The results of this rigorous clinical study prove that Bellafill® reduces the...

Read more

To category page